Why the study?
Does the addition of an ARB to full-dose ACE-inhibition provide additional clinical benefit in patients with hypertension, heart failure, or nephropathy?
Does the addition of an ARB to full-dose ACE-inhibition provide additional clinical benefit in patients with hypertension, heart failure, or nephropathy?
Answers are grounded in this paper and cite their sources.
Adding an ARB to full-dose ACE-inhibition may be beneficial in selected patients with persistent renin-angiotensin system activation.
Both angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers (ARBs) interfere with the activity of the renin-angiotensin system (RAS) in a different way. Theoretically, one might expect beneficial effects when they are used in combination, as a more complete suppression of the RAS can be achieved. But can this additional effect still be seen in patients on full-dose ACE-inhibition? Several controlled trials demonstrated that combination therapy can have additional benefits in hypertensive patients, in chronic heart failure patients, and in both diabetic and non-diabetic nephropathy patients. However, the clinical benefit was not always as pronounced as expected and not every patient will benefit from dual blockade of the RAS. There is some evidence of a less pronounced effect of combination therapy when a full dose of the ACE-inhibitor is given. However, it is well known that ACE-inhibitors cannot completely suppress the formation of angiotensin II, in particular, when the RAS is activated. Indeed, clinical trials indicated that add-on therapy with an ARB was especially of use when the RAS remained activated despite full-dose ACE-inhibitor treatment. In summary, combination of a full-dose ACE-inhibitor and an ARB can be a rational choice in selected patients.
No takes yet. Share an insight, caveat, or question.
Wal et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: